The effect of BeEAM regimen in transplantation of lymphoma patients

Phase 4

Recruiting

• Conditions: lymphoma.; Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue; C81-C96

• Registration Number: IRCT20180622040187N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 September 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

All the lymphoma patients from 18 to 65 years old that are candidate for autologous stem cell transplant

Exclusion Criteria

Not enough harvesting of CD34+ cells

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete remission of lymphoma within 6 months of transplantation. Timepoint: Six months after the transplant. Method of measurement: CT scan,measurement of lactate dehydrogenase and erythrocytes sedimentation rate.

Secondary Outcome Measures

Name	Time	Method
Hematologic toxicity. Timepoint: During hospitalization in the bone marrow transplantation ward. Method of measurement: Comlete blood count test.;Post transplant mortality. Timepoint: 100 days post transplant. Method of measurement: Physical examination.;The interval between stem cell infusion and transplantation. Timepoint: During hospitalization in transplantation ward. Method of measurement: Complete blood count test.;Non hematologic toxicity. Timepoint: 6months post transplantation. Method of measurement: Physical examination,liver and renal function tests.